HCW Biologics Inc.

For the period ended Mar 31, 2025. Filed May 15, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

HCWB$1.02-1.9%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance sheets

Condensed Balance Sheets

	December 31,	March 31,
	2024	2025
Unaudited
ASSETS
Current assets:
Cash and cash equivalents	$4,674,572	$1,107,613
Accounts receivable, net	582,201	87,493
Prepaid expenses	328,181	256,291
Other current assets	113,528	443,311
Total current assets	5,698,482	1,894,708
Investments	1,599,751	1,599,751
Property, plant and equipment, net	22,909,869	22,762,471
Other assets	28,476	28,476
Total assets	$30,236,578	$26,285,406
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Liabilities
Current liabilities:
Accounts payable	$22,332,261	$19,734,057
Accrued liabilities and other current liabilities	981,940	1,173,695
Short-term debt, net	6,314,684	6,234,338
Total current liabilities	29,628,885	27,142,090
Debt, net	7,377,865	7,705,364
Total liabilities	37,006,750	34,847,454
Commitments and contingencies (Note 9)
Stockholders’ deficit:
Common stock:
Common, $0.0001 par value; 250,000,000 shares authorized and 44,541,295 shares issued at December 31, 2024; 250,000,000 shares authorized and 44,934,120 shares issued at March 31, 2025	4,454	4,493
Additional paid-in capital	93,781,511	94,186,471
Accumulated deficit	(100,556,137)	(102,753,012)
Total stockholders’ deficit	(6,770,172)	(8,562,048)
Total liabilities and stockholders’ deficit	$30,236,578	$26,285,406

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.